Faeth Therapeutics, Inc.: 5%+ holders

As of November 10, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Faeth Therapeutics, Inc. The largest reported stake is VK Services, LLC's, at 10.2%. 11 filings are on record since February 25, 2026 (Schedule 13G, August 14, 2026).

S2G Investments, LLC also filed stake reports on 1 other company ↓

Sell to companies like Faeth Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Khosla Ventures VI, LP · Sole voting: 0 · Shared voting: 1,643,349 · Sole dispositive: 0 · Shared dispositive: 1,643,349 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: Caligan Partners LP · Sole voting: 0 · Shared voting: 629,467 · Sole dispositive: 0 · Shared dispositive: 629,467 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Trails Edge Capital Partners, LP · Sole voting: 515,335 · Shared voting: 0 · Sole dispositive: 515,335 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: StemPoint Capital LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-06-23 · Reporting person: S2G Investments, LLC · Sole voting: 2,575,401 · Shared voting: 0 · Sole dispositive: 2,575,401 · Shared dispositive: 0 · SCHEDULE 13G, 2026-06-23

Faeth Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2026-02-25. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Faeth Therapeutics, Inc. and the warning signs.

See Faeth Therapeutics, Inc.'s free Snapshot Watch Faeth Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Faeth Therapeutics, Inc. and the records around it.

Faeth Therapeutics, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Form D filing Mar 2026
• Who owns it

Companies that share a holder

• S2G Investments, LLC also filed stake reports on 1 other company: Once Upon a Farm, PBC (Feb 2026)
• Khosla Ventures VI, LP also filed stake reports on 2 other companies: BioAge Labs, Inc. (May 2026), Serve Robotics Inc. (Sep 2025)
• StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026), Xilio Therapeutics, Inc. (Aug 2026)

Want the whole picture on Faeth Therapeutics, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Faeth Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Faeth Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   17 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Faeth Therapeutics, Inc. by CUSIP 81728A207 and gives its principal executive office as 701 Tillery Street, #12 #1010, Austin, TX 78702 (SCHEDULE 13G, 2026-08-14).

What the percentages are based on

See responses to Item 11 on the attached cover pages, which are calculated based on 25,840,425 shares of Common Stock outstanding as of July 30, 2026, which is the total number of shares of Common Stock outstanding as reported in the Quarterly Report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on August 4, 2026.VK Services, LLC, SCHEDULE 13G, 2026-08-14

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein.Suvretta Capital Management, LLC, SCHEDULE 13G, 2026-06-23

Each Reporting Person may be deemed to beneficially own 0.0% shares of Common Stock, which is calculated based on 25,778,754 shares of Common Stock reported as issued and outstanding as of June 15, 2026, in Form 8-K filed with the Securities and Exchange Commission on June 18, 2026.StemPoint Capital LP, SCHEDULE 13G/A, 2026-08-14

Timeline

Swipe the table sideways to see every column.

Questions about who owns Faeth Therapeutics, Inc.

Who owns Faeth Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Faeth Therapeutics, Inc.: VK Services, LLC (10.2%, Schedule 13G, filed 2026-08-14), S2G Investments, LLC (9.99%, Schedule 13G, filed 2026-06-23) and Suvretta Capital Management, LLC (7.8%, Schedule 13G, filed 2026-06-23).

Who are the largest shareholders of Faeth Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Faeth Therapeutics, Inc. on this page are VK Services, LLC (10.2%), S2G Investments, LLC (9.99%) and Suvretta Capital Management, LLC (7.8%).

When did VK Services, LLC buy into Faeth Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from VK Services, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 10.2%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Faeth Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Faeth Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Faeth Therapeutics, Inc. is mentioned again
• Find former Faeth Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes